Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from SanBio Co ( (JP:4592) ) is now available.
SanBio Co. reported its consolidated financial results for the fiscal year ending January 31, 2025, showing a reduction in net losses compared to the previous year. Despite ongoing financial challenges, including negative operating and ordinary income, the company remains committed to its strategic goals, with no significant changes in accounting policies or consolidation scope.
More about SanBio Co
SanBio Co. is a company listed on the Tokyo Stock Exchange, operating in the biotechnology industry. The company focuses on developing regenerative cell medicines, aiming to address unmet medical needs in the field of neurological disorders.
YTD Price Performance: 40.86%
Average Trading Volume: 1,013
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $558.9M
Learn more about 4592 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue